JAZZ Sep 2024 145.000 call
| Previous Close | 3.1000 |
| Open | 3.1000 |
| Bid | 0.1000 |
| Ask | 5.0000 |
| Strike | 145.00 |
| Expire Date | 2024-09-20 |
| Day's Range | 3.1000 - 3.1000 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 1 |
PR NewswireZanidatamab Granted Priority Review for HER2-Positive Metastatic Biliary Tract Cancer
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review of the Biologics License Application (BLA) for zanidatamab, the human epidermal growth factor receptor 2 (HER2)-targeted bispecific antibody, for the treatment of previously treated, unresectable, locally advanced, or metastatic HER2-positive biliary tract cancer (BTC). Under the Prescription Drug User Fee Act (PDUFA), FDA has set a target action date
ACCESSWIREJazz Pharmaceuticals Announces Collaboration With Life Science Cares To Improve the Wellbeing of Under Resourced Communities Through Employee Volunteerism
Originally published by Jazz Pharmaceuticals DUBLIN, IRELAND / ACCESSWIRE / May 22, 2024 / Jazz Pharmaceuticals plc (Nasdaq:JAZZ) today announced a strategic collaboration with Life Science Cares to drive social impact through employee volunteerism ...
Insider MonkeyJazz Pharmaceuticals plc (NASDAQ:JAZZ) Q1 2024 Earnings Call Transcript
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Q1 2024 Earnings Call Transcript May 1, 2024 Jazz Pharmaceuticals plc isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Thank you for standing by. My name is Krista, and I will be your conference operator today. […]
